Rituximab

Form: IV Infusion; Subcutaneous

Strength: IV infusion: 100 mg/10 mL, 500 mg/50 mL; SQ: 1400 mg/11 mL

Reference Brands: Rituxan®(US), MabThera®, Truxima®(EU);Ruxience®(US)

Category: Oncology Cancer Care

Rituximab is a monoclonal antibody used for treating various hematologic cancers and autoimmune disorders. It targets CD20 on B cells, facilitating their destruction, and is effective for conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Available under Rituxan® in the US and MabThera® in the EU, Rituximab is supplied in IV infusion (100 mg/10 mL, 500 mg/50 mL) and subcutaneous (1400 mg/11 mL) formulations. Manufactured in GMP-compliant facilities, Rituximab is a trusted treatment option for oncology and autoimmune disease management, offering reliable solutions for pharma distributors across EU and US markets.